Extract
Judicious points are raised in correspondence by J. Messika and co-workers, as well as in the editorial by Glanville [1] accompanying our prior work regarding “Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis” [2]. Briefly, our study assessed the outcomes of a therapeutic approach to prospectively eradicate Pseudomonas aeruginosa from the respiratory tract in lung transplant recipients, using a susceptibility-directed targeted antibiotic treatment policy as of September 2011. We performed segmented time-based outcome analysis, investigating subsequent chronic lung allograft dysfunction (CLAD) development and graft survival. As hypothesised, based on the extensively documented detrimental effects of Pseudomonas aeruginosa in other respiratory disorders [3] and after lung transplantation [4–6], improved CLAD-free and graft survival, as well as better preserved pulmonary function over time, were seen in lung transplant recipients in whom Pseudomonas aeruginosa was successfully eradicated (n=76) versus those with persistent respiratory culture-positivity (n=19).
Abstract
Respiratory tract colonisation with Pseudomonas aeruginosa may represent a treatable trait to avert subsequent development of chronic lung allograft dysfunction in lung transplant recipients https://bit.ly/35rCVhW
Footnotes
Author contributions: R. Vos: wrote the manuscript; A. Van Herck: critically revised the manuscript.
Conflict of interest: R. Vos reports grants from Research Foundation-Flanders (FWO), outside the submitted work.
Conflict of interest: A. Van Herck has nothing to disclose.
Support statement: R. Vos is a senior clinical research fellow of the Fund for Scientific Research Flanders (FWO). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received January 7, 2021.
- Accepted June 9, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org